News & Press Release 2018-06-06Press Release Launch of RAPALIMUS® GEL 0.2% SAKIGAKE Designation & Orphan Drug Designation Treatment for Angiofibroma in Tuberous Sclerosis Complex[154 KB] 2018-05-31Press Release Announcement of Personnel Changes[43 KB] 2018-05-15Press Release Announcement of Private Placement of Shares to MEDIPAL HOLDINGS CORPORATION[118 KB] 2018-03-26Press Release Announcement of Personnel Changes[65 KB] 2018-03-26Press Release Marketing Approval Granted for RAPALIMUS GEL 0.2% (mTOR inhibitor), SAKIGAKE Designation & Orphan Drug Designation to Treat Angiofibroma in Tuberous Sclerosis Complex[51 KB] Nobelpharma About Nobelpharma Message from President & CEO Corporate Identity Philosophy Origin of Company Name History Company Company Profile Map & Directions Organization Chart Board Members Research & Development R&D of Nobelpharma Pipeline Products Financial Information Financial Highlights Financial Reports
